Furthermore, FBXO3 inhibitor monotherapy or combination with imatinib effectively eradicates CML-LSCs, overcomes TKI resistance, and spares normal hematopoiesis. Here, FBXO3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.